1007881-98-2

Basic information

• Product Name: (S)-tert-butyl 2-(5-(4-broMophenyl)-1h-iMidazol-2-yl)pyrrolidine-1-carboxylate
• Synonyms: (S)-tert-butyl 2-(2-(4-bromophenyl)-2-oxoethylcarbamoyl)pyrrolidine-1-carboxylate;tert-butyl (2S)-2-[[2-(4-bromophenyl)-2-oxoethyl]carbamoyl]pyrrolidine-1-carboxylate
• CAS NO: 1007881-98-2
• Molecular Formula: C₁₈H₂₃BrN₂O₄
• Molecular Weight: 392.29018
• EINECS: -0
• Mol File: 1007881-98-2.mol
• Article Data: 21

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (S)-tert-butyl 2-(5-(4-broMophenyl)-1h-iMidazol-2-yl)pyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-butyl 2-(5-(4-broMophenyl)-1h-iMidazol-2-yl)pyrrolidine-1-carboxylate(1007881-98-2)
• EPA Substance Registry System: (S)-tert-butyl 2-(5-(4-broMophenyl)-1h-iMidazol-2-yl)pyrrolidine-1-carboxylate(1007881-98-2)

Safety Data

• Hazardous Substances Data: 1007881-98-2(Hazardous Substances Data)

Usage

General Description

(S)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate is a chemical compound with a complex molecular structure. It contains a pyrrolidine ring, an imidazol ring, and a tert-butyl ester functional group. The compound also includes a bromophenyl group, which is a benzene ring with a bromine atom attached. This chemical may have potential applications in medicinal chemistry, due to its structural similarities with known pharmacologically active compounds. However, further research is needed to fully understand the properties and potential uses of (S)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate.

Upstream product

• 59936-29-7 (S)-N-(tert-butoxycarbonyl)proline methyl ester 
• 5467-72-1 α-amino-4-bromoacetophenone hydrochloride 
• 99-73-0 para-bromophenacyl bromide 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 7644-04-4 4-bromophenacylamine 

Downstream Products

• 1007882-04-3 (S)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1228552-27-9 ((S)-1-{(S)-2-[5-(4-bromophenyl)-1H-imidazol-2-yl]pyrrolidine-1-carbonyl}-2-methylpropyl)carbamic acid methyl ester 
• 1256386-05-6 1,1-dimethylethyl[2-(4'-{2-[(2S)-1-((2S)-3-methyl-2-{[(methyloxy)carbonyl] amino}butanoyl)-2-pyrrolidinyl]-1H-imidazol-4-yl}-4-biphenylyl)-2-oxoethyl]carbamate 
• 1272656-19-5 1,1-dimethylethyl 2-{N-[(methyloxy)carbonyl]-L-valyl}-3-(4-{4′-[2-((2S)-1-{N-[(methyloxy)carbonyl]-L-valyl}-2-pyrrolidinyl)-1H-imidazol-4-yl]-4-biphenylyl}-1H-imidazol-2-yl)-2,8-diazaspiro[4.5]decane-8-carboxylate 
• 1272656-21-9 1,1-dimethylethyl 2-((2S)-3-methyl-2-(((methyloxy)carbonyl)amino)butanoyl)-3-(((2-(4'-(2-((2S)-1-((2S)-3-methyl-2-(((methyloxy)carbonyl)amino)butanoyl)-2-pyrrolidinyl)-1H-imidazol-4-yl)-4-biphenylyl)-2-oxoethyl)amino)carbonyl)-2,8-diazaspiro[4.5]decane-8-carboxylate 
• 1272656-35-5 1,1-dimethylethyl 6-{N-[(methyloxy)carbonyl]-L-valyl}-7-(4-{4′-[2-((2S)-1-{N-[(methyloxy)carbonyl]-L-valyl}-2-pyrrolidinyl)-1H-imidazol-4-yl]-4-biphenylyl}-1H-imidazol-2-yl)-2,6-diazaspiro[3.4]octane-2-carboxylate 
• 1272656-37-7 1,1-dimethylethyl 6-((2S)-3-methyl-2-(((methyloxy)carbonyl)amino)butanoyl)-7-(((2-(4'-(2-((2S)-1-((2S)-3-methyl-2-(((methyloxy)carbonyl)amino)butanoyl)-2-pyrrolidinyl)-1H-imidazol-4-yl)-4-biphenylyl)-2-oxoethyl)amino)carbonyl)-2,6-diazaspiro[3.4]octane-2-carboxylate 
• 1272656-76-4 methyl [(1S)-2-methyl-1-({(2S)-2-[4-(4′-{2-[1-((2S)-3-methyl-2-{[(methyloxy)carbonyl]amino}butanoyl)-8-oxa-1-azaspiro-[4.5]dec-2-yl]-1H-imidazol-4-yl}-4-biphenylyl)-1H-imidazol-2-yl]-1-pyrrolidinyl}carbonyl)propyl]carbamate 
• 1272656-78-6 methyl ((1S)-2-methyl-1-(((2S)-2-(4-(4'-((((1-((2S)-3-methyl-2-(((methyloxy)carbonyl)amino)butanoyl)-8-oxa-1-azaspiro[4.5]dec-2-yl)carbonyl)amino)acetyl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)propyl)carbamate 
• 1272654-98-4 methyl [(1S)-1-({(2S)-2-[4-(4'-{2-[(3S,7S,9S)-7,9-dimethyl-2-((2S)-3-methyl-2-{[(methyloxy)carbonyl]amino}butanoyl)-6,10-dioxa-2-azaspiro[4.5]dec-3-yl]-1H-imidazol-4-yl}-4-biphenylyl)-1H-imidazol-2-yl]-1-pyrrolidinyl}carbonyl)-2-methylpropyl]carbamate 
• 1272655-00-1 C₄₅H₅₉N₇O₁₀ 
• 1272655-09-0 methyl ((1S)-1-methyl-2-{(3S)-3-[4-(4′-{2-[(2S)-1-((2S)-3-methyl-2-{[(methyloxy)carbonyl]amino}butanoyl)-2-pyrrolidinyl]-1H-imidazol-4-yl}-4-biphenylyl)-1H-imidazol-2-yl]-6,10-dioxa-2-azaspiro[4.5]dec-2-yl}-2-oxoethyl)carbamate 
• 1272655-11-4 methyl [(1S)-1-({(2S)-2-[4-(4'-{2-[(3S)-6,10-dioxa-2-azaspiro[4.5]dec-3-yl]-1H-imidazol-4-yl}-4-biphenylyl)-1H-imidazol-2-yl]-1-pyrrolidinyl}carbonyl)-2-methylpropyl]carbamate 
• 1272655-16-9 phenylmethyl (3S)-3-(4-{4'-[2-((2S)-1-{N-[(methyloxy)carbonyl]-L-valyl}-2-pyrrolidinyl)-1H-imidazol-4-yl]-4-biphenylyl}-1H-imidazol-2-yl)-6,10-dioxa-2-azaspiro[4.5]decane-2-carboxylate 

Relevant articles and documents

The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors

HCV NS5A inhibitors are the backbone of directly acting antiviral treatments against the hepatitis C virus (HCV). While these therapies are generally highly curative, they are less effective in some specific HCV patient populations. In the search for broader-acting HCV NS5A inhibitors that address these needs, we explored conformational restrictions imposed by the [7,5]-azabicyclic lactam moiety incorporated into daclatasvir (1) and related HCV NS5A inhibitors. Unexpectedly, compound 5 was identified as a potent HCV genotype 1a and 1b inhibitor. Molecular modeling of 5 bound to HCV genotype 1a suggested that the use of the conformationally restricted lactam moiety might have resulted in reorientation of its N-terminal carbamate to expose a new interaction with the NS5A pocket located between amino acids P97 and Y93, which was not easily accessible to 1. The results also suggest new chemistry directions that exploit the interactions with the P97-Y93 site toward new and potentially improved HCV NS5A inhibitors.

Monoglycosyl-containing heterocyclic compound for inhibiting hepatitis C viruses and preparation method

The invention discloses a monoglycosyl-containing heterocyclic compound for inhibiting hepatitis C viruses and a preparation method. The monoglycosyl-containing heterocyclic compound has a chemical structure represented by a formula I shown in the description. The monoglycosyl-containing heterocyclic compound disclosed by the invention can be used for effectively inhibiting protease of the hepatitis C viruses and treating infection of the hepatitis C viruses (HCV).

Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: From lead to clinical compound

Rapid clinical progress of hepatitis C virus (HCV) replication inhibitors, including these selecting for resistance in the NS5A region (NS5A inhibitors), promises to revolutionize HCV treatment. Herein, we describe our explorations of diverse spiropyrrolidine motifs in novel NS5A inhibitors and a proposed interaction model. We discovered that the 1,4-dioxa-7-azaspiro[4.4]nonane motif in inhibitor 41H (GSK2236805) supported high potency against genotypes 1a and 1b as well as in genotype 1b L31V and Y93H mutants. Consistent with this, 41H potently suppressed HCV RNA in the 20-day RNA reduction assay. Pharmacokinetic and safety data supported further progression of 41H to the clinic.